We next examined whether enhanced levels of STYK1 could reduce the sensitivity of NSCLC cells to afatinib by performing soft agar assays using PC9 cells constitutively overexpressing STYK1 (Fig. 2E). The gene discussed is STYK1; the disease is non-small cell lung carcinoma.